Kite Pharma (KITE) Posts Q1 Loss of 20c/Share

Kite Pharma (NASDAQ: KITE) reported Q1 EPS of ($0.20), $0.32 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $2.9 million versus the consensus estimate of $19.7 million.

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance